Form 4 - Statement of changes in beneficial ownership of securities:
SEC Accession No. 0000950170-25-074666
Filing Date
2025-05-19
Accepted
2025-05-19 18:33:25
Documents
1
Period of Report
2025-05-15

Document Format Files

Seq Description Document Type Size
1 4 ownership.html 4  
1 4 ownership.xml 4 5445
  Complete submission text file 0000950170-25-074666.txt   6872
Mailing Address 60 LEVERONI COURT NOVATO CA 94949
Business Address 60 LEVERONI COURT NOVATO CA 94949 415-483-8800
Ultragenyx Pharmaceutical Inc. (Issuer) CIK: 0001515673 (see all company filings)

EIN.: 272546083 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)

Mailing Address C/O MOLECULAR TEMPLATES, INC. 9301 AMBERGLEN BLVD, SUITE 100 AUSTIN VI 78729
Business Address
Sanders Corazon (Corsee) D. (Reporting) CIK: 0001796536 (see all company filings)

Type: 4 | Act: 34 | File No.: 001-36276 | Film No.: 25965519